Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

Novartis faces short-term challenges with patent expirations but shows long-term growth potential. Click here to read why I ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

The U.S. Court of Appeals for the Federal Circuit (CAFC) today issued a precedential decision reversing a district court’s ...

The Federal Circuit reversed a Delaware district court’s 2023 ruling axing a Novartis Pharmaceuticals Corp. patent covering ...

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian ...

Initial clinical data from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader (MGD) MRT-6160 expected in Q1 2025Additional clinical ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities ...

Marea Therapeutics reports MAR001 reduced remnant cholesterol by ~50% in Phase 2a trial; plans Phase 2b within 6 months.

Survivors of childhood cancer face challenges from bone mineral density (BMD) deficits due to treatment exposures and other ...